Efficacy of eribulin following anthracycline and taxane in patient with triple negative breast cancer.

Trial Profile

Efficacy of eribulin following anthracycline and taxane in patient with triple negative breast cancer.

Suspended
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Eribulin (Primary) ; Taxanes (Primary) ; Anthracyclines
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Most Recent Events

    • 12 Oct 2017 Primary Endpoint (Pathological complete response (pCR) rate) has been not met, according to results presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Oct 2017 New trial record
    • 12 Sep 2017 Results (n=13) assessing efficacy of eribulin following anthracycline and taxane in triple negative breast cancer, were presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top